Formycon stock
FYB.DEXETRAFormycon AG, HealthcareISIN DE000A1EWVY8WKN A1EWVY
30Score 30 out of 100, Weak
Price and trend
25 / 100
Price history
−31% in one yearThe chart shows daily closes over 16 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 23% below it.
Since February 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 21).
The price is 43% below its 52-week high. Largest decline in 16 years: 85% (January 2023 to November 2026).
Chart figures for advanced users
- SMA 50$20.97
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$21.56
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)21
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$15.62
- The lowest closing price of the last twelve months.
- Resistance$28.92
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Formycon AG belongs to the Biotechnology industry (Germany) and, with a market value of $293.75M, is number 288 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $49.28M (down 36.2% year on year) and a loss of $71.69M.
- For fiscal 2026, analysts expect on average revenue of $85.61M (up 73.7%) and adjusted earnings per share of −$0.46.
Show more
- MEQIRI Score 30 out of 100 (Weak): rank 676 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $57.38M, financial debt $9.44M.Stability 57
Weaknesses
- DilutionShare count up 61% since 2020.Capital allocation 18
- Loss-makingLoss of $27.85M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$6.23M over the last 12 months.Fundamentals 17
The score is held back by profitability and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 31 to 30.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- weak momentum
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
OvervaluedNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 18.3% on the twelve months before. Revenue has grown strongly since 2012, at around 56% per year. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 8%, operating −66%, net −145%. Last 12 months: net −41%. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 29 Apr 2027in 167 days
- Last reported
- 12 Aug 2026EPS reported −$0.91 (expected −$0.16)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 1,486.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.46−1,486.7%
- Revenue
- $85.61M−4.4%
- Earnings per share
- $1.41−34.2%
- Revenue
- $121.82M−6.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Formycon
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 30
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AgomAb TherapeuticsAGMB $313.22M30
- AltimmuneALT $313.17M24
- Kyverna TherapeuticsKYTX $311.07M28
- Vicore Pharma HoldingVICO.ST $310.09M38
- Turn TherapeuticsTTRX $307.62M44
- Nautilus BiotechnolgyNAUT $303.15M40
- MapLight TherapeuticsMPLT $301.31M32
- Heidelberg PharmaHPHA.DE $105.76M28
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 14 Feb 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.